Related to Ghent University to Leverage Roche´s LightCycler® 1536 Instrument for Cancer Research

• Optimata and Teva to Repurpose Shelved Cancer Drug Candidates
  
• Morphotek Taps Synageva in Cancer and Infectious Disease Deal
  
• Repros Gets an Extension from NIH for Deadlines Related to Lead Anticancer Agent
  
• Tarceva Given after Initial Chemotherapy Improves Survival in NSCLC Patients
  
• Roche’s Xeloda Improves Disease-Free Survival after Colorectal Cancer Surgery
  
• OSI to Pay $20M to Broaden Cancer Partnership with AVEO
  
• GSK and Enigma to Develop Point-of-Care Flu Diagnostic
  
• BioFocus DPI and Oncodesign Ally to Provide Oncology Drug Discovery Services
  
• Apogenix Obtains Roughly $3.66M to Further Cancer and Inflammatory Disease Initiatives
  
• Covance Takes Over Merck & Co.’s Gene-Expression Lab and Gains $145M Contract
  
• FDA Gives Roche’s Avastin the Go-Ahead for Metastatic Renal Carcinoma
  
• ImmunoVaccine Technologies Collaborates with Scancell to Advance DNA Vaccine Delivery
  
• Horizon Gains Patents to Cell Lines that Model Genetic Mutations Seen in Cancer
  
• Vernalis Earns $6M Up Front in Oncology Deal with GSK
  
• Viral Genetics Forms Anticancer Subsidiary to Exploit Metabolic Disruption Technology
  
• Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics
  
• Biota and Daiichi Sankyo’s Flu Therapy Shows Positive Phase III Results
  
• Beckman Coulter Creates Genomics Services Company
  
• Facet Biotech Steps Up to Help Trubion Advance Early-Stage Anticancer Agent with a $20M Fee
  
• Polish University to Use Cellectricon’s Transfection System